Apricus Biosciences (NASDAQ:APRI) reports that it will file a new drug submission in Canada for MycoVa in the fourth quarter of next year. In advanced testing, MycoVa has exhibited an ability to kill nail fungus while enhancing the appearance of nails.
Stryker Corporation (NYSE:SYK) chooses Kevin Lobo as its president and chief executive, and also names him to the board. Lobo joined Stryker’s Orthopaedics group in 2011, following several years at Johnson & Johnson (NYSE:JNJ). Interim Chief Executive Curt Hartman will exit the firm after assisting in a search for a permanent chief financial officer.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Sunshine Heart (NASDAQ:SSH) wins a conditional FDA approval to move into a fourth quarter evaluation for its C-Pulse Heart Assist System. The firm says that a trail using 388 patients will see half being implanted with the system as part of a series of “timely approvals”.
Six months of Roche Holding’s (RHHBY.OB) Herceptin breast-cancer treatment is no more effective than one year’s worth, according to key studies. Had the study turned out in reverse, there was a risk of $1.5 billion in lost revenue, as about one-half of the drug would have been necessary for the same effect. However, it now appears that extending treatment to two years also doesn’t look worthwhile, which places a maximum on Roche’s ability to squeeze out more from the drug before the patent expiration in 2014.
Don’t Miss: Xstrata Backs This New Buyout Bid.